Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.42 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19985024 | 0.86 | SLC6A9 (0.43) | P2RX7SLC6A9EIF4A3NR1H2NR1H3 | |
| SCHEMBL19971958 | 0.79 | MAPT (0.47) | ATMTP53MAPTSMN1; SMN2 | |
| SCHEMBL19985023 | 0.72 | SLC6A9 (0.47) | SLC6A9EIF4A3NR1H2NR1H3POLB | |
| SCHEMBL18286135 | 0.69 | HSP90AA1 (0.52) | P2RX7ATMHSP90AA1 | |
| SCHEMBL15506284 | 0.68 | MAPT (0.69) | POLBMAPTSMN1; SMN2 | |
| SCHEMBL19985025 | 0.68 | ABCB1 (0.43) | P2RX7ATMEIF4A3MAPT | |
| SCHEMBL14257956 | 0.66 | P2RX7 (0.60) | P2RX7TP53MAPTSMN1; SMN2 | |
| SCHEMBL3183964 | 0.66 | ALDH1A1 (0.63) | MAPTSMN1; SMN2 | |
| SCHEMBL18283321 | 0.65 | PREP (0.62) | ATMHSP90AA1POLB | |
| SCHEMBL19710253 | 0.65 | NOTUM (0.54) | SLC6A9NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079730-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORP (US) | 2018-03-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079730-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | PCSK9, PCSK7, PCSK6 | P2RX7 4831/4885ATM 2396/4885SLC6A9 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.